Skip to main content

International Journal of Clinical Oncology

Ausgabe 10/2023

Inhalt (14 Artikel)

Open Access Special Article

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition

Saori Mishima, Yoichi Naito, Kiwamu Akagi, Naomi Hayashi, Akira Hirasawa, Tomoro Hishiki, Ataru Igarashi, Masafumi Ikeda, Shigenori Kadowaki, Hiroaki Kajiyama, Motohiro Kato, Hirotsugu Kenmotsu, Yasuhiro Kodera, Keigo Komine, Takafumi Koyama, Osamu Maeda, Mitsuru Miyachi, Hiroshi Nishihara, Hiroyuki Nishiyama, Shouichi Ohga, Wataru Okamoto, Eiji Oki, Shigeru Ono, Masashi Sanada, Ikuo Sekine, Tadao Takano, Kayoko Tao, Keita Terashima, Katsuya Tsuchihara, Yasushi Yatabe, Takayuki Yoshino, Eishi Baba

Special Article

Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

Satoru Muto, Takeshi Matsubara, Takamitsu Inoue, Hiroshi Kitamura, Kazuhiro Yamamoto, Taisuke Ishii, Masahiko Yazawa, Ryohei Yamamoto, Naoto Okada, Kiyoshi Mori, Hiroyuki Yamada, Takashige Kuwabara, Atsushi Yonezawa, Takuya Fujimaru, Haruna Kawano, Hideki Yokoi, Kent Doi, Junichi Hoshino, Motoko Yanagita

Special Article

Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

Hiroyuki Nishiyama, Takamitsu Inoue, Yuichi Koizumi, Yusuke Kobayashi, Hiroshi Kitamura, Kazuhiro Yamamoto, Takashi Takeda, Takehito Yamamoto, Ryohei Yamamoto, Takeshi Matsubara, Junichi Hoshino, Motoko Yanagita

Special Article

Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

Yuichi Ando, Hiroyuki Nishiyama, Hideki Shimodaira, Nao Takano, Emiko Sakaida, Koji Matsumoto, Koki Nakanishi, Hideki Sakai, Shokichi Tsukamoto, Keigo Komine, Yoshinari Yasuda, Taigo Kato, Yutaka Fujiwara, Takafumi Koyama, Hiroshi Kitamura, Takashige Kuwabara, Atsushi Yonezawa, Yuta Okumura, Kimikazu Yakushijin, Kazuki Nozawa, Hideaki Goto, Takeshi Matsubara, Junichi Hoshino, Motoko Yanagita

Special Article

Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022

Kenji Ishikura, Kenji Omae, Sho Sasaki, Yugo Shibagaki, Satoko Ichioka, Yusuke Okuda, Kenichiro Koitabashi, Koichi Suyama, Takuro Mizukami, Chihiro Kondoh, Sumio Hirata, Takeshi Matsubara, Junichi Hoshino, Motoko Yanagita

Original Article

Acid suppressants reduce the therapeutic effect of immune checkpoint inhibitors and increase the risk of acute kidney injury: a meta-analysis

Keisuke Okamoto, Yoshitaka Saito, Atsushi Yamaguchi, Yoh Takekuma, Mitsuru Sugawara

Open Access Original Article

First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

Makoto Nishio, Yuichiro Ohe, Satoshi Ikeda, Toshihide Yokoyama, Hidetoshi Hayashi, Tatsuro Fukuhara, Yuki Sato, Hiroshi Tanaka, Katsuyuki Hotta, Shunichi Sugawara, Haruko Daga, Isamu Okamoto, Kazuo Kasahara, Tateaki Naito, Li Li, Ravi G. Gupta, Judith Bushong, Hideaki Mizutani

Open Access Correction

Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

Makoto Nishio, Yuichiro Ohe, Satoshi Ikeda, Toshihide Yokoyama, Hidetoshi Hayashi, Tatsuro Fukuhara, Yuki Sato, Hiroshi Tanaka, Katsuyuki Hotta, Shunichi Sugawara, Haruko Daga, Isamu Okamoto, Kazuo Kasahara, Tateaki Naito, Li Li, Ravi G. Gupta, Judith Bushong, Hideaki Mizutani

Original Article

Clinical significance of intraperitoneal paclitaxel combined with systemic chemotherapy for gastric cancer with peritoneal metastasis

Taiki Nakashima, Takaaki Arigami, Yoshikazu Uenosono, Daisuke Matsushita, Masataka Shimonosono, Yusuke Tsuruda, Ken Sasaki, Kenji Baba, Hiroshi Kurahara, Takao Ohtsuka

Original Article

Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study

Naohisa Yoshida, Yoshiaki Kuriu, Jun Ikeda, Michihiro Kudou, Toshihiko Kirishima, Tetsuya Okayama, Koji Miyagawa, Tsuyoshi Takagi, Masayoshi Nakanishi, Toshifumi Doi, Takeshi Ishikawa, Yoshito Itoh, Eigo Otsuji

Original Article

Clinical significance of metastatic tumor deposit foci in rectal cancer in the lateral pelvic lymph node area

Daisuke Yamai, Yoshifumi Shimada, Masato Nakano, Hikaru Ozeki, Akio Matsumoto, Kaoru Abe, Yosuke Tajima, Mae Nakano, Hiroshi Ichikawa, Jun Sakata, Takahiro Nagai, Yiwei Ling, Shujiro Okuda, Gen Watanabe, Hitoshi Nogami, Satoshi Maruyama, Yasumasa Takii, Toshifumi Wakai

Open Access Original Article

Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study

Hiroyuki Nishiyama, Toyonori Tsuzuki, Chikara Ohyama, Hideyasu Matsuyama, Kenta Shinozaki, Yuko Hayashi, Nobuya Hayashi, Ryo Koto, Eisei Shin, Osamu Ogawa

Original Article

Ovarian serous borderline tumors with recurrent or extraovarian lesions: a Japanese, retrospective, multi-institutional, population-based study

Tsukasa Baba, Masafumi Koshiyama, Masahiro Kagabu, Yoshiki Mikami, Sachiko Minamiguchi, Suzuko Moritani, Mitsuya Ishikawa, Aikou Okamoto, Yasuhisa Terao, Toru Nakanishi, Hidetaka Katabuchi, Hideki Tokunaga, Toyomi Satoh, Ikuo Konishi, Nobuo Yaegashi

Original Article

Retrospective study of the efficacy and safety of docetaxel/carboplatin combination therapy as postoperative adjuvant chemotherapy for nonsquamous cell carcinoma of the cervix

Ryo Koike, Mayu Yunokawa, Kohei Omatsu, Nozomi Kurihara, Hidetaka Nomura, Hiroyuki Kanao, Akihiko Sekizawa

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.